RxDoctor Payments Data

Charito Quintero Howard, MD

Psychiatry · Towson, MDNPI 1265493860

Payments from drug & device makers

$566in general payments, 2019–2025

Across 19 payments — averaging $29.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$280
  • Corium, LLC$87
  • Alkermes, Inc.$61
  • Adlon Therapeutics L.p.$36
  • Ironshore Pharmaceuticals Inc.$16
  • Neuronetics, Inc.$16
  • plus $71 from 5 others

What the payments were for

  • Food & beverage$566100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$566 in reported general payments places this provider in the 70th percentile of 851 psychiatry providers in Maryland.

See all psychiatry providers in Maryland

Medicare billing

Part B allowed, 2024
$154,183
Medicare patients
63
Services billed
1,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl17$67,509
CaplytaLumateperone Tosylate29$58,962
VraylarCariprazine Hcl36$53,131
VyvanseLisdexamfetamine Dimesylate38$22,648
RexultiBrexpiprazole13$20,739
FetzimaLevomilnacipran Hcl22$10,250
DayvigoLemborexant19$8,338
TrintellixVortioxetine Hydrobromide12$5,783
BelsomraSuvorexant11$4,606
Lurasidone Hcl11$3,925
Aripiprazole49$3,471
Quetiapine Fumarate ErQuetiapine Fumarate26$2,773
Lisdexamfetamine Dimesylate12$2,734
Methylphenidate ErMethylphenidate Hcl35$2,100
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine28$1,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$280$67,50917 claims
AbbVieVraylar, Fetzima$15$63,38158 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$14$58,96229 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix$13$28,43150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 851 psychiatry providers in Maryland.

Other psychiatry in Towson

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →